AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

The study consisted of: * A 30-day screening phase prior to Day 1 * Day 1 registration and pre-treatment paracentesis * Aflibercept administration within 1-day of registration * Two-week study treatment cycles (for efficacy data, the cut-off date was 6 months post-registration * A 60-day post-treatment follow-up phase During the study, participants were treated with Aflibercept study treatment through the duration of the study unless they met one the following criteria for discontinuation: * Participant (or legal representative) chose to withdraw from treatment * The investigator or sponsor thought that continuation of the study would be detrimental to the participants well-being * Participant had intercurrent illness that prevented further administration of investigational product (IP) * Participant had more than 2 IP dose reductions * Participant had unacceptable adverse events (AEs) * Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset angina, or worsening of preexisting angina * Participant required surgical intervention for intestinal obstruction or gastrointestinal perforation